Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
03 sept. 2024 09h00 HE
|
Longeveron
Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
26 août 2024 16h05 HE
|
Longeveron
Longeveron to present at HC Wainwright global investment conference.
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 16h05 HE
|
Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
05 août 2024 16h05 HE
|
Longeveron
Longeveron announced that it will report Q2 2024 financial results and provide a business update on Wednesday, August 14, 2024.
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
28 juil. 2024 16h51 HE
|
Longeveron
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
19 juil. 2024 16h05 HE
|
Longeveron
Longeveron announces closing of previously announced registered direct offering, raising $9 million in gross proceeds.
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
18 juil. 2024 08h45 HE
|
Longeveron
Longeveron announces $9.0 million registered direct offering.
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
17 juil. 2024 08h00 HE
|
Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
10 juil. 2024 07h30 HE
|
Longeveron
Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
Neha Motwani Elected to Longeveron® Board of Directors
09 juil. 2024 09h00 HE
|
Longeveron
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors